Square Pharmaceuticals Future Growth
Future criteria checks 2/6
Square Pharmaceuticals is forecast to grow earnings and revenue by 13.2% and 11.1% per annum respectively. EPS is expected to grow by 13.4% per annum. Return on equity is forecast to be 18.1% in 3 years.
Key information
13.2%
Earnings growth rate
13.4%
EPS growth rate
Pharmaceuticals earnings growth | 16.8% |
Revenue growth rate | 11.1% |
Future return on equity | 18.1% |
Analyst coverage | Low |
Last updated | 04 Feb 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2026 | 90,892 | 27,725 | 15,996 | 28,645 | 3 |
6/30/2025 | 81,075 | 24,667 | 16,563 | 26,067 | 3 |
6/30/2024 | 71,990 | 21,495 | 14,004 | 23,058 | 3 |
12/31/2023 | 67,469 | 19,599 | 12,088 | 13,911 | N/A |
9/30/2023 | 65,137 | 19,480 | 9,620 | 11,800 | N/A |
6/30/2023 | 62,748 | 18,980 | 5,721 | 8,546 | N/A |
3/31/2023 | 62,020 | 18,856 | 6,968 | 10,289 | N/A |
12/31/2022 | 60,782 | 19,143 | 6,252 | 10,594 | N/A |
9/30/2022 | 58,791 | 18,680 | 6,859 | 12,222 | N/A |
6/30/2022 | 57,598 | 18,157 | 6,692 | 12,875 | N/A |
3/31/2022 | 56,713 | 18,526 | 8,514 | 14,936 | N/A |
12/31/2021 | 54,834 | 17,819 | 8,307 | 14,183 | N/A |
9/30/2021 | 53,004 | 17,012 | 9,070 | 13,949 | N/A |
6/30/2021 | 50,703 | 15,947 | 7,178 | 10,976 | N/A |
3/31/2021 | 49,021 | 14,484 | 7,344 | 10,544 | N/A |
12/31/2020 | 48,395 | 14,237 | 9,532 | 12,249 | N/A |
9/30/2020 | 47,158 | 13,933 | 7,903 | 10,427 | N/A |
6/30/2020 | 45,876 | 13,354 | 8,718 | 10,760 | N/A |
3/31/2020 | 46,360 | 13,733 | 10,203 | 12,019 | N/A |
12/31/2019 | 45,138 | 13,236 | 9,780 | 11,586 | N/A |
9/30/2019 | 44,785 | 12,831 | 10,780 | 12,455 | N/A |
6/30/2019 | 44,034 | 12,646 | 10,343 | 12,392 | N/A |
3/31/2019 | 42,322 | 12,168 | 8,101 | 10,525 | N/A |
12/31/2018 | 41,252 | 12,025 | 6,645 | 9,288 | N/A |
9/30/2018 | 40,328 | 11,754 | 6,276 | 9,493 | N/A |
6/30/2018 | 39,654 | 11,594 | 6,738 | 9,905 | N/A |
3/31/2018 | 39,474 | 11,667 | 5,777 | 9,371 | N/A |
12/31/2017 | 39,131 | 11,622 | 6,754 | 10,071 | N/A |
9/30/2017 | 37,978 | 11,222 | N/A | 9,723 | N/A |
6/30/2017 | 36,543 | 10,637 | N/A | 9,542 | N/A |
3/31/2017 | 35,584 | 10,330 | N/A | 9,806 | N/A |
12/31/2016 | 34,534 | 9,893 | N/A | 9,348 | N/A |
9/30/2016 | 33,448 | 9,639 | N/A | 10,637 | N/A |
6/30/2016 | 33,074 | 9,199 | N/A | 9,615 | N/A |
12/31/2015 | 29,642 | 7,770 | N/A | 9,487 | N/A |
9/30/2015 | 28,400 | 7,091 | N/A | 8,298 | N/A |
6/30/2015 | 27,531 | 6,411 | N/A | 7,223 | N/A |
3/31/2015 | 25,979 | 6,032 | N/A | 6,246 | N/A |
12/31/2014 | 25,858 | 5,060 | N/A | 5,586 | N/A |
9/30/2014 | 25,511 | 5,122 | N/A | 5,763 | N/A |
6/30/2014 | 24,176 | 5,002 | N/A | 5,513 | N/A |
3/31/2014 | 23,268 | 4,945 | N/A | 6,416 | N/A |
12/31/2013 | 23,018 | 4,988 | N/A | 7,217 | N/A |
9/30/2013 | 22,304 | 4,677 | N/A | 6,640 | N/A |
6/30/2013 | 21,540 | 4,477 | N/A | 6,320 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SQURPHARMA's forecast earnings growth (13.2% per year) is above the savings rate (3.7%).
Earnings vs Market: SQURPHARMA's earnings (13.2% per year) are forecast to grow slower than the BD market (13.7% per year).
High Growth Earnings: SQURPHARMA's earnings are forecast to grow, but not significantly.
Revenue vs Market: SQURPHARMA's revenue (11.1% per year) is forecast to grow faster than the BD market (8.1% per year).
High Growth Revenue: SQURPHARMA's revenue (11.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SQURPHARMA's Return on Equity is forecast to be low in 3 years time (18.1%).